2016.01.04 08 10 48Reena Nair cv 2016 .pdf

File information


Original filename: 2016.01.04_08-10-48Reena Nair cv 2016.pdf
Title: Are You suprised ?
Author: LSK

This PDF 1.5 document has been generated by Microsoft® Office Word 2007, and has been sent on pdf-archive.com on 11/09/2018 at 16:55, from IP address 94.231.x.x. The current document download page has been viewed 511 times.
File size: 514 KB (15 pages).
Privacy: public file


Download original PDF file


2016.01.04_08-10-48Reena Nair cv 2016.pdf (PDF, 514 KB)


Share on social networks



Link to this file download page



Document preview


CURICULUM VITAE
Name: Reena Nair
Gender: Female
Date of Birth: 09/11/1960
Designation: Senior Consultant, Department of Clinical Hematology, TATA Medical Centre, Kolkata
Educational Qualification:
: Doctor of Medicine (MD), Postgraduate degree in Internal Medicine, from Bombay University.
1988
1983

:

Bachelor of Medicine and Bachelor of Surgery(MB BS) Graduate degree, from Bombay University,
with first class honours and distinction in Human Anatomy

Details of Training and Experience:
Internship
: From January 1984 to December 1984, at the Goa Medical College Hospitals,
Goa.
Junior Residency

:

From March 1985 to March 1988, in the Department of Medicine at the Goa
Medical College Hospital, Goa.

Registrar

:

March 1988 to December 1988, Intensive Care Unit, Department of Medicine, PD
Hinduja National Hospital, Bombay.

Junior Residency

:

January-December 1989, Department of Medical Oncology, Tata Memorial
Hospital, Bombay.

Senior Residency

:

January to December 1990, Department of Medical Oncology, Tata Memorial
Hospital, Bombay.

Research Fellow

:

January 1992 to June 1994, Department of Medical Oncology, Tata Memorial
Hospital, Bombay.

Clinical Observer

:

July 1994 to September 1994, Department of Clinical Oncology, Royal
Postgraduate Medical School, Hammersmith Hospital, London.

Pool Officer – (Research
Associate)

:

November 1994 to July 1996, Department of Medical Oncology, Tata Memorial
Hospital, Mumbai.

Clinical Appointments:
Lecturer and Assistant
Medical Oncologist

:

August 1996 to October 2001, Department of Medical Oncology, Tata Memorial
Hospital, Mumbai

Associate Professor &
Medical Oncologist

:

November 2001 to November 2004, Department of Medical Oncology, Tata
Memorial Hospital, Mumbai

Additional Professor &
Medical Oncologist

:

November 2004 to November 2008, Department of Medical Oncology, Tata
Memorial Hospital, Mumbai

Professor and Medical
Oncologist

:

November 2008 to July 2012, Department of Medical Oncology, Tata Memorial
Hospital, Mumbai

1

Convener – Hemato
Lymphoid (-Adult)
Senior Consultant, Clinical
Hematology and Medical
Oncology

:

January 2009 onwards to March 2012, Department of Medical Oncology, Tata
Memorial Hospital, Mumbai
October 2012 onwards, Tata Medical Center, Kolkata

Administrative Appointment
S. No
Office held and organization
1.

Member, Executive committee: Mumbai Hematology Group 1997.

2.

Treasurer, Indian Oncology Study Group, Mumbai 2001-2012.

3.

Joint Secretary, Mumbai Hematology Group 2004.

4.

Member (co-opted), Executive committee, Indian Society of Medical & Pediatric Oncology 2004 -2006.

5.

Treasurer: Indian Breast Group 2004-2006

6.

Founding Member: Myeloma India Foundation 2004

7.

Indian APL Study Group: Member 2004 onwards

8.

Scientific Committee Member, Tata Memorial Hospital, 2004 – 2006.

9.

Human Ethics Committee Member, Tata Memorial Hospital, 2007- 2011.

10.

Founder Member, Developing countries task force, Breast International Group, 2008.

11.

Founder Member “Registry for epidemiology end results and analysis in lymphomas (REEA-L), Indian
Oncology Study Group 2009.

12.

Invited Faculty, Australian and Asia Pacific Clinical Oncology Research Development (ACORD).
September 2010, 2012 and 2014.

13.

Invited Member, Scientific Advisory Committee, National Institute of Immuno- Hematology, ICMR,
KEM Hospital, Mumbai, June 2011.

14.

Invited member of the International Data Safety Monitoring Committee (DSMC), for Sandoz
Biopharmaceuticals, Germany, 2011-2013.

15.

Steering Committee member and Invited Faculty, Australian and Asia Pacific Clinical Oncology
Research Development (ACORD), September 2012- September 2014.

16.

Institute Review Board Member, ACTREC, Tata Memorial Centre, 2012.

17

Executive Committee member and Invited Faculty, Australian and Asia Pacific Clinical Oncology
Research Development (ACORD), September 2014- September 2016.

18.

Invited member of the International Data Safety Monitoring Committee (DSMC), for Sanofi
Pharmaceuticals, 2015-2017.

2

Memberships
S. No
Year

Role and organization

1.

1995

Mumbai Hematology Group: Life member

2.

1997

Indian Society of Medical & Pediatric Oncology: Life Member.

3.

1998

Indian Breast Group: Life Member.

4.

2004

European Society of Medical Oncology (ESMO): Member 2004 - 2012

5.

2004

Scientific Committee Member, Tata Memorial Hospital, 2004 – 2006

6.

2004

Myeloma India Foundation: Founder Member 2004

7.

2004

Indian APL Study Group: Member 2004 onwards.

8.

2005

American Society of Clinical Oncology (ASCO): Member 2005 -2012

9.

2007

Indian Oxford (INDOX) Trials Group- Principle Investigator for Hemato- Lymphoid
malignancies, 2009 - 2014.

10.

2011

American Society of Hematology (ASH): Member 2011 - 2012

DM TEACHER/ THESIS EXAMINER- Medical Oncology
S.No Year
Institutes
1.

2005
onwards

Department of Medical Oncology, Tata Memorial Centre: Have been Guide to four students,
Examiner, as well as Convener of examinations.

2.

2008

Department of Medical Oncology, Gujarat Cancer Research Institute, Ahmedabad.

3.

2011/ 2012

Department of Medical Oncology, Examiner at All India institute of Medical Sciences, Rotary
Cancer Institute, New Delhi.

4.

2012

Department of Medical Oncology, Cancer Institute, Adiyar Chennai (COPE for all India DM
candidates) - Faculty.

5

2015

Department of Medical Oncology, Thesis Reviewer, Shere Kashmir Medical College, Srinagar
Jammu & Kashmir.

Clinical Research Projects - Investigator Initiated Clinical Trials
No.
Title of the approved trial
1.

Phase II trial of amifostene in myelodysplastic syndrome - Department Protocol. Trial Co-ordinator.
Completed in March 1998

2.

Phase III trial of BEP chemotherapy versus VIP chemotherapy in testicular germ cell tumours Department Protocol. Trial Co-ordinator. Completed in August 1998.

3.

UKCCCR Adjuvant Endocrine Therapy and Chemotherapy in women with Early Breast Cancer (ABC)
Trial: Approval 1998, Accrual completed Sept 2000. Co-investigator & later Principal Investigator

4.

Alternating Triple Therapy Regimen in Adult Aggressive Lymphomas (B-Cell Type): Correlation with
distinct biologic entities. - Department Protocol 1998  approved by the Indian Council Medical
Research (ICMR). Accrual completed April 2003. Co-investigator & later Principal Investigator

5.

All Trans-Retinoic Acid along with Daunomycin followed by Arsenic Trioxide as Sequential Therapy in

3

Acute Promyelocytic Leukaemia: Correlation of hematologic and cytogenetic remission. Department
Audit. Accrual completed July 2000. Co-investigator & later Principal Investigator
6.

Analysis of immunophenotype, IgH chain variable Intramural N region genes and chemokine SDF1/CXCR4 interaction in B – Cell Chronic Lymphocytic Leukemia or Small Lymphocytic NonHodgkin’s Lymphoma, an Intramural TMC Grant. Co-investigator. Approved for Intra-mural funding
2002. Accrual completed 2003

7.

EORTC Protocol No. 10951 (Amendment n2) titled as “Randomized phase II - III study in first line
hormonal treatment for metastatic breast cancer with EORTC Exemestane or Tamoxifen in
Postmenopausal patients". Co-investigator & later Principal Investigator. Completed follow up
completed in May 2004

8.

Molecular Remission with Arsenic trioxide in acute promyelocytic leukemia. Indian APML Study
Group Trial sponsored by Department of Biotechnology (DBT). Co-Principal Investigator at TMH.
Ethics Committee approval 2005, Accrual completed 2008. Follow up completed 2012.

9.

Timing of systemic chemotherapy in isolated loco regional recurrence in patients with Breast cancer.
(Approved by Ethics Committee Aug 2005). Principal Investigator. Sponsored partly by Women’s
Cancer Initiative (WCI). Study closed in 2010.

10.

A prospective study of the fungal serology in the early diagnosis of fungal infections in patients of
acute leukemia, high grade non Hodgkin’s lymphoma, hematopoietic stem cell transplantation
presenting with infection/ fever and high risk neutropenia. Ethics Committee approval March 2006.
Sponsored by Pfizer (unconditional research grant). Principal Investigator

11.

Application of FDG PET and molecular profiling for risk stratification of diffuse large B cell non
Hodgkins Lymphoma in different ethnic populations. International Atomic Energy Agency (IAEA).
Ethics Committee Approval June 2008, enrollment completed June 2011. Principal Investigator

12.

Establishment of Registry for Epidemiology and End Results Analysis in Lymphomas (REEA-L),
Mumbai. Sponsored by Dr Reddy’s Laboratory (Unrestricted Educational Grant) Ethics Committee
Approval June 2010. Principal Investigator

13.

Establishment of National Lymphoma Registry (R-Lymph 20). Sponsored by Roche (Unrestricted
Research Grant). Ethics Approval June 2011. Principal Investigator

14.

Comparison of efficacy and safety of Rituximab (Mabthera) and its biosimilar (Reditux) in diffuse
large B cell lymphoma (DLBCL) patients treated with chemo immunotherapy: A retrospective
analysis. Ethics Approval July 2011. Principal Investigator – (student thesis).

15.

Treatment results of advanced stage Hodgkin’s lymphoma: A retrospective study. Ethics Approval July
2011. Principal Investigator- (student thesis).

16.

An observational bioequivalence study of two Rituximab formulations in patients with diffuse large B
cell lymphomas. Ethics Approval Sept 2011. Co- Investigator

17.

Patient generated Subjective Global assessment to predict early outcomes in Lymphoma. Ethics
Approval Sept 2011. Principal Investigator- (student thesis).

18.

Development of a registry to assess the demography, cytogenetic profile and treatment outcomes of
patients with multiple myeloma- Mumbai Myeloma Program. Ethics Approval March 2012. CoInvestigator.

19.

Immunohistochemical Immuno-histochemistry and Molecular profiling of large B-cell lymphomas with respect to
double hit lymphomas. Ethics committee approval awaited 2015. Co- Principal
Investigator

Sponsored Clinical Trials
S.No.
1.

Phase III multicentre trial of Tamoxifen versus Droloxefene in the management of advanced and recurrent
breast cancers sponsored by Pfizer. Trial Co-ordinator. Completed in September 1998.

4

2.

Evaluation of the effect of early intervention with epoetin alfa on anaemia in cancer patients receiving
platinum-based chemotherapy sponsored by Johnson & Johnson. Co-Investigator. Completed in
December 1998

3.

Phase III multicentre trial of idoxifene 40 mg/ day versus tamoxifen 20 mg/ day as first line hormonal
therapy of metastatic breast cancer in post menopausal women sponsored by SmithKline Beecham. CoInvestigator Completed in September 1999

4.

Phase III multicentre trial of TLC D-99 doxorubicin and cyclophosphamide versus doxorubicin and
cyclophosphamide in the treatment of metastatic breast cancer sponsored by Quintiles Spectral India Ltd.
Trial Co-ordinator. Completed in March 1999

5.

Phase III multicentre trial of docetaxel in the dose of 100mg and 75mg in treatment of advanced breast
cancers sponsored by Rhone Poulenc (Rorer). Trial Co-ordinator. Completed in August 1998

6.

A double-blind randomized placebo-controlled parallel-group study looking at the effect of intranasal IM
862 on the overall tumour response rate as an add-on to conventional chemotherapy in Breast Cancer
sponsored by Nicholas Piramal India Ltd. Co-Investigator. Completed in Sept 2000. Co-investigator

7.

A Single-blind Randomized Phase 3 Trial of MTA plus Cisplatin versus Cisplatin in Patients with
Malignant Pleural Mesothelioma sponsored by Eli-Lilly Ranbaxy Ltd. Accrual completed in October
2000. Follow up completed in May 2004. Co-investigator & later Principal Investigator

8.

Protocol CA002-0LD : Multicentre Study of a Cremophor ® - Free, Protein Stabilized, Nanoparticle
Formulation of Paclitaxel (ABI-007) in-Patients with Stage IV Metastatic Breast Cancer’ sponsored by
Quintiles Spectral (I) Ltd. Accrual completed in October 2001. Follow up completed in May 2004. Coinvestigator

9.

Protocol B9E-MC-S197 titled as Randomized Phase II Trial of Gemcitabine combined with a Taxane
for Metastatic Breast Cancer. Completed in Sept 2003 sponsored by Eli Lilly. Co-Investigator.
(Abstract presented at ASCO 2004). Co-investigator

10.

A Multicentric Phase I Clinical and Pharmacological Study of DRF 1042, a Novel
Camptothecin
Analog given orally in Adult Patients with Refractory
Solid Tumors Approved by the Ethics
Committee in November 2001. Sponsored By
Dr. Reddy's Research Foundation. Principal
Investigator

11.

Phase 3 trial of LY900003 PLUS Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in
patients with advanced, previously untreated Non Small Cell Lung Cancer Sponsored by Eli Lilly.
Approved by the Ethics Committee in November 2001. Principal Investigator

12.

Protocol Number BO16216E/H2223g: A randomized, controlled, open label study to evaluate the
efficacy and safety of Herceptin® (trastuzumab) in combination with the oral aromatase inhibitor
Arimidex® (anastrozole) compared with Arimidex® alone as first and second line treatment
administered to postmenopausal, hormone receptor positive (ER+ve and/or PR+ve) patients with
HER2 overexpressing metastatic breast cancer, sponsored by Roche. Approved June 2003. Accrual
completed Jan 04. Follow up completed May 2005. Co-investigator & later Principal Investigator

13.

A randomized trial of Pivanex plus Docetaxel or Docetaxel Monotherapy resistant advanced non-small
cell Carcinoma of the Lung (NSCLC)”, sponsored by Quintiles Spectral India. Co-investigator.
Approved in Sept 2003. Accrual completed in April 2004. Follow up completed 2004. Coinvestigator & later Principal Investigator

14.

A phase III Study (Tesmilifene) Combined with epirubicin and Cyclophosphamide versus epirubicin
and Cyclophosphamide alone as first line treatment in metastatic or Recurrent Breast Cancer. Scientific
Committee approval June-04. Pharm-Olam International (UK) Ltd. Accrual completed Sept 2005.
Trial completed in 2007. Principal Investigator

15.

A randomized, double blind, parallel group, multicentre, Phase III study comparing the efficacy and
tolerability of fulvestrant (faslodex) 500 mg with fulvestrant (faslodex) 250 mg in postmenopausal
women with estrogen receptor positive advanced breast cancer progressing or relapsing after previous
endocrine therapy, sponsored by Quintiles Spectral India. Approved by Ethics Committee Aug 2005.
Accrual started Jan 2006. Trial completed in 2010. Principal Investigator.

16.

A phase 3 randomized, double-blind study of oral CCI-779 administered in combination with letrozole
versus letrozole alone as first line hormonal therapy in postmenopausal women with locally advanced

5

or metastatic breast cancer. Approved by Ethics Committee Nov 2005. Accrual started Jan 2006. Study
close out Nov 2006. Principal Investigator.
17.

A phase III randomized controlled trial of myocet, trastuzumab and paclitaxel versus trastuzumab and
paclitaxel for first line therapy of metastatic breast cancer. Study protocol STM01-102. Approved by
Ethics Committee Oct 2006. Accrual completed in Nov 2007. Follow up ongoing 2011. Principal
Investigator.

18.

Efficacy and safety of SIIL recombinant Human Granulocyte colony stimulating factor, r-PEG –Hu
GCSF, PEG SILGRASTIM in the correction of neutropenia in patients with solid tumor/ lymphomas
undergoing myelosuppressive chemotherapy when compared to Filgrastim. Approved by Ethics
Committee Oct 2006. Accrual started in Nov 2006. Trial close out in Aug 2008. Principal
Investigator.

19.

Protocol No 16835-D An open label randomized phase II study of two different dosing regimens of
capecitabine in combination with intravenous docetaxel (q3w) in patients with locally advanced and/or
metastatic breast cancer. Approval by Ethics Committee March 2007). Accrual started in Apr 2007.
Status: Completed. Principal Investigator.

20.

Project EGF 105485: A randomized, double blind, multicenter, placebo controlled study of adjuvant
Lapatinib in women with early stage ErbB2 overexpressing breast cancer. Approval by Ethics
Committee in April 2007. Accrual: Completed. Follow up: Ongoing. Principal Investigator.

21.

Phase III study of vinflunine plus gemcitabine versus paclitaxel plus gemcitabine in patients with
unresectable, locally recurrent of metastatic breast cancer after prior anthracycline based adjuvant
chemotherapy” Project No. 429 Principal Investigator Ethics Approval: 10th Aug ’07 Status:
Stopped for excessive toxicity

22.

A phase 3 clinical study to investigate the prevention of relapse in lymphoma using Daily Enzastaurin
(Project No: 578) Ethics Approval: 31.7.08, Status: Closed. Principal Investigator.

23.

Project (ALTTO EGF106708) a randomized, Multicentre, Open-label, Phase III study of adjuvant
Lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ ErbB2 positive
primary breast cancer. Ethics approval Sept 2008 Status: Ongoing. Principal Investigator.

24.

Single-arm, open-label, multicenter Phase II study to evaluate the efficacy and safety of P276-00 in
patients with relapsed and/or refractory mantle cell lymphoma. EC Approval: 18.12.09 Status:
Closed. Principal Investigator.

25.

A Randomized, Multi-center, Double- blind, Parallel Group study to compare the pharmacokinetics,
Pharmacodynamics, Safety and Efficacy of two anti- CD 20 monoclonal antibodies in combination
with GHOP in patients with CD 20 – positive Diffuse Large B-Cell Lymphoma. [Protocol ID : RI-02001]. EC Approval: 03.12.13 Status: Ongoing. Principal Investigator.

26.

A multicenter, Retrospective medical record review study to describe real-world treatment patterns and
safety among patients receiving rituximab [Mabthera or Reditux] to treat B-Cell non Hodgkin
Lymphoma in India. [Protocol ID : RI-02-002]. EC Approval: 11.08.14 Status: Completed.
Principal Investigator.

27.

Reditux Registry to compare Effectiveness, Safety, and Resource Utilization of Reditux vs the
reference Medicinal product to treat Diffuse Large B –Cell lymphoma and Chronic Lymphatic
Leukemia in Routine Clinical Practice [Protocol ID : RI-02-003]. EC Approval: 09.07.15 Status:
Ongoing. Principal Investigator.

Publications- Original papers
1.
Nair R. Ulcerative colitis: dissertation for MD Medicine, Bombay University, Bombay. (MD Thesis)
2.
Athale UH, Nair R, Kadam P, Pai SK, Advani SH. Acute leukaemia in Down's syndrome. Indian
Paediatrics. 1990; 27(1): 3-5.
3.
Athale UA, Nair R, Iyer R, Nair CN, Kadam P, Advani SH. Chronic myelomonocytic leukaemia: an
analysis of fourteen consecutive cases. J Assoc Phys India. 1991; 39(5): 390-3.

6

4.

5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.

Nair R, Athale UA, Iyer RS, Nair CN, Pai SK, Kurkure PA, Kadam PR, Advani SH. Childhood
myelodysplastic syndromes: clinical features, cytogenetics and prognosis. Indian J Paediatrics. 1992; 59(4):
443-8.
Nair R, Kane SV, Borges A, Advani SH. Giant cell fibroblastoma. J Surg Oncol 1993; 53(2):136-9.
Nair R, Krishnamurthy s, Advani SH. Maxillary extragonadal germ cell tumor: a case report. Ind J Cancer
1993; 30: 202-204.
Nair R, Iyer RS, Nair CN, et al. Myelodysplastic syndromes: a clinical and pathological analysis of 88
patients. Indian J Cancer 1993; 30: 169-175.
Nair R, Kane SV, Borges A, Advani SH. Giant cell fibroblastoma. J Surg Oncol 1993; 53 (2): 136-139.
Nair R, Advani SH. Management of acute leukaemia: present concept. Indian Pediatr 1993; 30: 589-591.
Nair R, Pathak AB, Saikia T, Advani SH. Bone marrow rescue using recombinant human GM-CSF: a report
of two cases. Indian J Hematol 1993; 11: 18-21.
Nair R, Gopal R. The treatment of intermediate and high grade non Hodgkin’s lymphoma in adults. Indian J
Hematol Blood Trans 1994; 12: 152-156.
Nair R, Pai SK, Saikia TS, Nair CN, Kurkure PA, Gopal R, Sampat MS, Advani SH. Malignant germ cell
tumor in childhood. J Surg Oncol 1994; 56: 186-190.
Nair R, Advani SH. Pediatric Hemato-oncology in India. Pediatric Hematol Oncol 1994; 11: 129-134.
Gopal R, Nair R, Saikia TK, et al. Modified MACOP-B chemotherapy. J Assoc Phys India 1994: 42: 781784.
Kadam P, Dadabhoy K, Bhise A, Athale U, Nair R, Advani SH. Chromosome investigations and clinical
outcome in patients with myelodysplastic syndrome. Ind J Med Res 1995; 101: 163-169.
Advani H Suresh, Nair Reena. Medical Emergencies in Oncology. Nat. Med J 1995; 8: 273-276

17.

Gauri K, Advani SH, Nair CN, Pai SK, Kurkure PA, Nair R, Saikia TK, Vege D, Desai PB. Pediatric germ
cell tumor: An experience with BEP. J Ped Hematol/ Oncol 1995; 17: 318- 324.

18.

Nair Reena, Gopal R, Saikia K Tapan, Advani H Suresh. MINE Therapy for patients with resistant or
relapsed non-Hodgkins lymphoma. Ind J Med & Ped Oncol 1996; 17: 90 - 98.

19.

Nair R, Saikia TK, Gopal R, et al. Low dose cytosine arabinoside in the treatment of myelodysplasitic
syndrome. J Assoc Phys India 1996; 44: 181- 183.

20.

Advani SH, Kochupillai V, Lalitha N, Shanta V, Maitreyan V, Nair Reena, Banerjee U, Kelkar R,
Mukerjee S. Infections in the immunocompromised host: A prospective multicentre survey in patients
receiving chemotherapy for acute leukemia. J Assoc Phys Ind 1996; 44: 769-773.

21.

Bapna A, Nair R, Advani SH. The “Retinoic Acid Syndrome” in acute promyelocytic leukemia and its
management. Ind J Med & Ped Oncol 1997;18: 46-50.

22.

Nair R, Advani SH. Cancer- Home Care Management. Current Med J – North zone, 1998; IV(1): 50-53.

23.

Nair R, Advani SH : Medical Emergencies in Oncology. Current Med J - North zone, 1998; IV (2): 26-32.

24.

Advani SH, Nair R. Medical Oncology Department, Tata Memorial Hospital. Ped Hemat Oncol 1998; 15:
109-115.

25.

Nair R, Nair CN, Advani SH. All Trans Retinoic Acid with Low dose Cytosine arabinoside in the treatment
of Myelodysplastic Syndrome. Leuk & Lymph 1998; 29: 187-192.

26.

Bapna A, Nair R, Saikia TK All trans retinoic acid (ATRA) in Paediatric Acute Promyelocytic Leukemia.
Ped Hemat & Oncol 1998; 15: 243-248.

27.

Nair R, Gopal R, Nair N, Saikia TK, Parikh PM, Joshi SR, Soman CS, Muckaden M, Dinshaw KA, Advani
SH. Non Hodgkins Lymphoma : A randomised comparison of efficacy and toxicity of epirubicin versus
doxorubicin. Cancer 1998; 82: 2282 – 2288.

28.

Advani SH, Nair R, Bapna A, Gladstone B, Kadam P, Saikia TK, Parikh PM, Gopal R, Nair CN. Acute
Promyelocytic Leukemia: All-trans Retinoic Acid (ATRA) with Chemotherapy is superior to ATRA alone.
Am J of Hemat 1999; 60: 87-93.

29.

Gupte S, Nair R, Naresh KN, Borges AM, Soman CS, Gopal R, Advani SH. MALT Lymphoma of Nasal
Mucosa Treated with Antibiotics. Leuk & Lymph 1999; 36 : 195-197.

7

30.

Dhiraj Abhyankar, R Nair, Hari Menon, Bhupendra Kapur, Suresh Advani. Avascular Necrosis of Head of
Femur in a Patient with Acute Promyelocytic Leukemia. Leuk & Lymph 2000; 37: 635-637.

31.

Kapur B, Nair R, Gopal R, Abhyankar D, Naresh K, Laskar S, Muckaden M, Advani S. Primary cardiac
Lymphoma – A Case Report. IJHBT Dec 2000;18: 94-95.

32.

PS Amre,(Kadam), C Baisane, TK Saikia, R Nair, H Gawade, SH Advani. Fluorescence in situ
hybridization: a highly efficient technique of molecular diagnosis, also a sensitive tool for prediction of
future course of disease in patients with myeloid leukemia. Cancer Gen Cytogen 2001:131;125-134.

33.

Agarwal B, Ramanathan U, Lokeshwar N, Nair R, Gopal R, Bhatia K, Naresh KN. Lymphoid Neoplasms
in HIV - Positive Individuals in India. J Acquir Immun Def Syndr 2002: 29 (2): 181-183.

34.

Reena Nair, Lokeshwar NM, Myelodysplastic Syndrome (MDS). Ind J Hemat & Bld Trans 2002; XX
No 3: 73-79.

35.

Indumati Ambulkar, Reena Nair. Primary Ovarian Lymphoma: Report of Cases and Review of Literature.
Leuk Lymph 2003; 44 (5): 825-827.

36.

Advani SH, Nair Reena, et al. Febrile Neutropenia: Indian Guideline 2004.

37.

Deshmukh C, Bakshi A, Parikh P, Nair R, et al. Primary Non-Hodgkins Lymphoma of the bone: a single
institute experience. Med Oncol 2004; 21:

38.

Biswas g, Khurana R, Bhagwat R, Nair R, Banavali SD, Vora A, Parikh PM. Necrotizing fascitis in Acute
lymphoblastic leukemia. JAPI 2004; 52: 890.

39.

Sharma LM, Biswas G, Rai SS, Nair R, Gupta S, Parikh PM. Retroperitoneal
report and review of literature. Ind J Cancer 2004; 41: 133- 134.

40.

TK Saikia, A Bakshi, R Bhagwat, S Tawde, R Nair, CN Nair, PM Parekh. Outcome in adults: A
retrospective analysis. Natl Med J India 2005; 18: 12-15.

41.

Ghanshyam Biswas, Chetan Deshmukh, Ashish Bakshi, Reena Nair, Sudeep Gupta, Sumeet Gujral,
Purvish M Parekh. Primary Uterine Lymphoma treated by adjuvant chemotherapy after radical surgery. W
JCO 2005; MS 962549958112431.

42.

S Chopra, G Bahl, M Ramadwar, S Ramani, R Nair, MA Muckaden, S Laskar. Synchronous mucosaassociated lymphoid tissue (MALT) lymphomas involving bilateral orbits and breasts: a rare clinical
entity. Leuk Lymph 2005, 46 (8): 1247 – 1250.

43.

Ghanshyam Biswas, Parekh M Purvish, Reena Nair, Roshni Bhagwat, Kumar Prabhash, Amish Vora,
Sudeep Gupta, VR Pai, Hari Menon, PSRK Sastry. Rituximab (Anti CD 20 monoclonal antibody) in
Lymphoproliferative Malignancies: Tata Memorial Hospital Experience. JAPI 2006; 54: 29-33.

44.

Parmar V, Krishnamurthy A, Nadkarni MS, Hawaldar R, Sarin R, Chinoy R, Nair R, Thakur M, Jalali R,
Gupta S, Shet T, Budrukkar A, Ramani S, Dinshaw KA, Badwe RA.Breast conservation treatment in women
with locally advanced breast cancer. Int J Surg Oncol 2006; 4: 106-114.

45.

Kumar Prabhash, Ghanshyam Biswas, Reena Nair, Durgatosh Pandey, Dipen Maru, Aparna Mahajan,
Purvish Parekh. Metachronous gastric diffuse large B-cell lymphoma and adenocarcinoma. Ind J Gastro
2006; 25: 261- 262.

46.

Kei Siong Khoo, Syed Hasan M Zaidi, V Srimunnimit, S Song, Reena Nair, Corazon A Ngelangel, Anita
Bustam, William H H Reece, Manfred Lehnert. Gemcitabine and split-dose paclitaxel or docetaxel in
metastatic breast cancer: a randomized phase II study. Eur J Oncol 2006; 42: 1797-1806.

47.

Siddhartha Laskar, Mary Ann Muckaden, Gaurav Bahl, Sandeep De, Reena Nair, Sudeep Gupta, Ashish
Bakshi, Kumar Prabhash, Dipen Maru, Sumeet Gujral, Purvish Parikh, Shyam Kishore Shrivastava, &
Ketayun Ardeshir Dinshaw. Primary Non-Hodgkin’s Lymphoma of the Nasopharynx: Prognostic Factors
and Outcome of 113 Indian Patients. Leuk Lymph 2006; 47(10): 2132 – 2139.

48.

The Adjuvant Breast Cancer Trials Collaborative Group. Polychemotherapy for early Breast Cancer
Chemotherapy Randomized Trial. J Natl Cancer Inst 2007; 99: 506-515.

49.

The Adjuvant Breast Cancer Trials Collaborative Group. Ovarian abalation or suppression in
premenopausal early breast cancer: results from the International Adjuvant Breast Cancer ovarian abalation
or suppression Randomized Trial. J Natl Cancer Inst 2007; 99: 516-525.

8

plasmacytoma: A case

50.

Pranjali K, Prabhash K, Karanth VN, Kane S, Nair R, Parikh PM. Umbilical metastasis: an unusual
presentation of pancreatic adenocarcinoma. Ind J Dermat Venerol Lepro 2007; 73: 199-200.

51.

Karanth VN, Pranjali K, Sudeep Gupta, Reena Nair, Purvish M Parikh. Cryptosporidiosis in a relapsed case
of Hodgkins Disease. Ind J Med Sci 2007; 61: 419-421.

52.

Siddhartha Laskar, Gaurav Bahl, Mary Ann Muckaden, Reena Nair, Sudeep Gupta, Ashish Bakshi,
Sumeet Gujral, Tanuja Shet, Shyam Kishore Shrivastava, Ketayun Ardeshir Dinshaw. Primary diffuse
large B-Cell lymphoma of the tonsil: is a higher radiotherapy dose required? Cancer 2007; 110/4: 816823.

53.

R Nair, K Prabhash, M Sengar, A Bakshi, S Gujral, S Gupta, P Parikh. The effect of short –term intensive
chemotherapy on reactivation of tuberculosis. Ann Oncol 2007; 18: 1234-1245.

54.

Sheetal Hingmire, Sachin Hingmire, Ashish Baksi, Sumeet Gujral, Rajan Badwe, Reena Nair. Multiple
myeloma mimicking bone metastasis in a patient with carcinoma breast. Ind J Med/ Ped Oncol 2008; 29: 5355.

55.

S Gujral, A Agarwal, V Gota, R Nair, S Gupta, SK Pai, M Sengar, T Shet, PG Subramanium, M Mukaden,
S Laskar. A clinicopathological study of mantle cell lymphoma in a single centre in India. Ind J Pathol/
Micro 2008; 51: 315-322.

56.

K Prabhash, Vikram GS, R Nair, M Sengar, S Gujral, A Bakshi, S Gupta, PM Parikh. Fludarabine in
Lymphoproliferative malignancies: A single centre experience. Natl Med Journal 2008; 21: 171-174.

57.

A Chogule, S Pomlampalli, P Amre, S Shinde, S Banavali, K Prabhash, R Nair, PG Subramanium, S Gujral,
PM Parikh. Identification of PML/ RARa fusion gene transcripts that showed no t(15;17) with conventional
karyotyping and fluorescent in situ hybridization. Gen & Mol Res 2009; 8: 1 – 7.

58.

Suryaprakash VG, Purandhare NC, Gujral S, Shah S, Nair R, Rangarajan V. Positron emission tomography
evaluation of primary Hodgkins disease of liver. Ind J Cancer 2009; 46: 216- 218.

59.

Prabhash K, Medhekar A, Biswas S, Kurkure PA, Nair R, Kelkar R. Comparison of in vitro activities of
ceftazidime, piperacillin-tazobactam, and cefaperazone-sulbactum, and the implication on empirical therapy
in patients with cancer. Ind J Cancer 2009; 46: 318- 322.

60.

Sumeet Gujral, Sunita Polampalli, Y Badrinath, Ashok Kumar, Subramanium PG, Reena Nair, Sudeep
Gupta, Manju Sengar, Chandrika Nair. Immunophenotyoing of mature B-cell non Hodgkin’s lymphoma
involving bone marrow and peripheral blood: critical analysis and insights gained at a tertiary care cancer
hospital. Leuk Lymph 2009; 50: 1290- 1300.

61.

Shubhada Kane, Aditi Khurana, Gorakh Parulkar, Tanuja Shet, Kumar Prabhash, Reena Nair, Sumeet
Gujral. Minimum diagnostic criteria for plasmablastic lymphoma of oral/ sinonasal region encountered in a
tertiary cancer hospital in the developing country. J Oral Path 2009; 38:138-144.

62.

Gujral S, Polampalli S, Badrinath Y, Kumar A, Subramanian PG, Nair R, Sengar M, Nair C. Immuno
phenotyping of mature T/NK cell neoplasm presenting as leukemia. Indian J Cancer. 2010 Apr-Jun; 47
(2): 189-93.

63.

Prabhash K, Medhekar A, Ghadyalpatil N, Noronha V, Biswas S, Kurkure PA, Nair R, Kelkar R. Blood
stream infections in cancer patients: A single centre experience of isolates and sensitivity pattern. Ind J
Cancer 2010; 47: 184-188.

64.

H Kim Lyerly, Aky P Abernethy, Martin R Stockler, Bogda Koczwara, Zeba Aziz, Reena Nair, Lesley
Seymour. Need for Global Partnership in cancer care: Perceptions of cancer care researchers attending the
2010 Australia and Asia Pacific Clinical Oncology Research Development Workshop. J Oncol Practice
2011; 7: 1-6.

65.

Reena Nair, Vikas Ostwal, Manju Sengar, Amol Kothekar, Jiggeshu Divetia, Urmila Thate. Lead
Intoxication mimicking a malignancy. Hematol Oncol Stem cell Ther 2011; 4 (2) 146-147.

66.

Manju Sengar, Amol Akhade, Reena Nair, Hari Menon, Epari Sridhar, Sumeet Gujral, Tanuja Shet,
Siddharth Laskar. Retrospective audit of clinicopathological attributes and treatment outcomes of Adolescent
and Young Adults non Hodgkins Lymphoma from a Tertiary Care Centre. Ind J Med & Pediatr Oncol 2011;
32:(4) 197-203.

9

67.

Shilpa Gupta, Bhausaheb Bagel, Sumeet Gujral, P G Subramanian, Navin Khattry, Hari Menon, Reena
Nair. Parenthood in patients of Acute Promyelocytic leukaemia after treatment with Arsenic trioxide - A
case series. Leuk Lymph 2012; 53:2192-2194.

68.

Rakesh Katna, Tanuja Shet, Manju Sengar, Hari Menon, Siddharth Laskar, Prabhash Kumar, Anil D’Cruz,
Reena Nair. Clinico-Pathological study and outcome analysis of thyroid lymphomas: Experience from a
tertiary care centre. Head & Neck 2013; 35(2):165-171.

69.

Kadam Amre PS, Gadage V, JainH, Nikhaje S, Manju S, Mittal N, Gujral S, Nair R. Clinicopathological
impact of cytogenetic subgroups in B-cell chronic lymphocytic leukemia: Experience from India. Ind J
Cancer 2013; 50 (3): 261-267.

70.

Shilpa Gupta, Reena Nair, Hari Menon, Sumeet Gujral, PG Subramanian. Therapy related acute
promyelocytic leukemia following breast cancer treatment- a case report. JAPI (Sent for publication-Jr No:
244/2011)

71.

Partha S Roy, Shiji John, Sadashiv Karnakal, Sadhana Kannan, Preeti Pawaskar, Jayant Gawande,
Bhausaheb Bagal, Navin Khattry, Manju Sengar, Hari Menon, Sumeet Gujral, Reena Nair. Comparison of
efficacy and safety of Rituximab (Mabthera) and its biosimilar (Reditux) in DLBCL patients treated with
chemo immunotherapy: a retrospective analysis. Ind J of Med & Ped Oncol 2013; 34 (4) 292- 298.

72.

Ramesh Nimmaguda, Raghunandharao Digumarti, Reena Nair, Dinesh Bhurani, Vinod Raina, Shyam
Agarwal, Shekhar patil, Pabitra Gogai, Subramanian Sundaram, Chanchal Goswami, Shashikant Apte,
Srinivas Chakravathy, Anand Pathak. The Epidemiology of lymphomas and treatment outcomes of Diffuse
Large B cell Lymphoma: Retrospective Analysis from India. Ind J of Med & Ped Oncol 2013; 34 (4) 299304.

73.

Brijesh Arora, Vikram Gota, Hari Menon, Manju Sengar, Reena Nair, Pankaj Patial, Sripad S Banavali.
Therapeutic drug monitoring for imatinib. Current status and Indian experience. Ind J of Med &Ped Oncol
2013; 34 (3) 224- 228.

74.

Laskar Sidharth, Tabassum Khanna, Menon Hari, Sengar Manju Sengar, Sumeet Gujral, Tanuja Shet,
Shridhar Epari, Rangarajan Venkatesh, Muckaden Maryann, Nair Reena, Banavali Shripad. Radiation
therapy for early stage unfavourable Hodgkins Lymphomas: Is dose reduction feasible? Leuk Lymp 2013; ID
871631

75.

Paul Goss, Kathrin Strasser- Weippi, Bruttany L Lee- Bychkovsky......., Reena Nair, .......The Lancet
Oncology Commission Challenges to effective cancer control in China, India and Russia. The Lancet
Oncology 2014; 15(5): 489 – 538.

76.

PM Parikh, S Gupta, S Dawood, H Rugo............., R Nair, D Doval. ICON 2013: Practical consensus
recommendations for hormone receptor – positive HER 2- negative advanced or metastatic breast cancer.
Ind J Cancer 2014:51(1): 73-79.

77.

Juliano Cerci, Tamas Gyorke, Francisca Redonda, Jim P Morris, Claudio Meneghetti, Chirayu Auewarakul,
Reena Nair, Charity Gorospe, June-key Chung, Isinsu Kuzu, Monica Celli, Rose Ann Padua, Maurizio
Dondi, Robert Carr. Prospective International cohort study demonstrates inability of interim PET to predict
treatment failure in diffuse large B cell lymphoma. J Nuc Med 2014 / 561043

78.

Hemant Malhotra, Prantar Chakrabarti, Vikram Mathews, Jina Bhattacharyya, Tulika Seth, K Gayathri,
Hari Menon, P G Subramanian, Ajay Sharma, Maitreyee Bhattacharyya, P K Gogoi, Reena Nair, SVSS
Prasad, MarieTherese, Manipadam , Neelam Varma, AK Vaid, Subhash Varma, MB Agarwal, Shyam
Aggarwal, Usha Agarwal. Myeloproliferative Neoplasm Working Group (MPN-WG) consensus

10

Recommendations for diagnosis and management of Primary Myelofibrosis, Polycythemia Vera and
Essential Thrombocythemia. ISMPO, 2014: 03/2015; 36(1). DOI:10.4103/0971-5851.151770
79.

Robert Carr, Stefano Fanti, Diana Paez, Juliano Julio Cerci, Tamas Gyorke, Francisca Redondo, Tim P
Morris, Claudio Meneghetti, Chirayu Auewarakul, Reena Nair, Charity Gorospe, June-Key Chung, Isinzu
Kuzu, Monica Celli, Sumeet Gujral, Rose Ann Padua, Maurizio Dondi, Hilal Ozdağ. Prospective
International Cohort Study demonstrates inability of Interim PET to predict treatment failure in Diffuse
Large B-Cell Lymphoma. Journal of Nuclear Medicine 11/2014; 55(12). DOI:10.2967 /jnum

80.

Neeraj Arora, Indu Arun, Anupam Chakrapani, Reena Nair. Classical Hodgkin lymphoma with coexistant
plasma cell neoplasm: a case report. Indian Journal of Pathology and Microbiology 10/2014; 57(4):656-658.
DOI:10.4103/0377-4929.142726

81.

Sriram Ravichandran, Monali Gupta, Mayur Parihar, Anupam Chakrapani, Reena Nair, Mammen Chandy.
Plasma cell leukemia: a management conundrum.12/2014; 2014(9):159-61. DOI:10.1093/omcr/ omu060.

82.

H Kim Lyerly · Maria R Fawzy · Zeba Aziz · Reena Nair · C S Pramesh · Vani Parmar · Purvish M
Parikh · Rozmin Jamal ·Azizunissa Irumnaz · Jun Ren · Martin R Stockler · Amy P Abernethy Regional
Variation in Identified Cancer Care Needs of Early-Career Oncologists in China, India, and Pakistan. The
Oncologist 04/2015; 20(5). DOI:10.1634/theoncologist.2014-0213

83.

Hasmukh Jain, Manju Sengar, Nair Reena, Siddharth Laskar, Tanuja Shet, Sumeet Gujral, Epari Sridhar.
Treatment Results in advanced stage Hodgkins Lymphoma: a retrospective study. Journal of Postgraduate
Medicine 04/2015; 61(2):88-91. DOI:10.4103/0022-3859.150446

84.

Neeraj Arora, Aroonima Mishra, Poonam Santra, Reena Nair. Hairy cell leukemia with ascites and
coexistent histoplasmosis. Indian Journal of Pathology and Microbiology 02/2015; 58(1):125-6.
DOI:10.4103/0377-4929.151215

85.

Sriram Ravichandran , Rohith G. Chitrapur, Saurabh Bhave, Anupam Chakrapani, Reena Nair, Mammen
Chandy. Systemic Mastocytosis with Associated Clonal Hematological Non-Mast Cell Lineage Disorder
(MDS-RCMD): A Difficult Disease to Diagnose and Treat. J Indian Journal of Hematology and Blood
Transfusion. 2015 DOI 10.1007/s12288-015-0594-2.

Publication –Book Chapters
1.

Advani SH, Nair R. Advances in pediatric oncology. In. Gupta S (ed) Recent advances in pediatrics, 1994 pp
301-23.

2.

Nair R, Advani SH. Acute Leukaemia’s. In Manual of Medical Emergencies, published by MM Health Care
Pvt. Ltd.1997 pp 388 – 394.

3.

Nair Reena. Molecular studies in leukemias: Practical Importance. Ixth National CME in Hematology,
2003, by Dr M B Agarwal. Pg 137-146.

4.

Nair Reena, Advani SH. Acute Leukemias in the Mannual of Medical Emergencies, 2nd edition, 2003 pg 600620.

5.

Advani SH, Saikia TK, Gopal R, Nair Reena et al. Febrile Neutropenia: Indian Guidelines, Indian Society of
Medical & Pediatric Oncology 2004.

6.

Reena Nair, Sheetal Acute Promyelocytic Leukemia. Hematology Update – 2006. Practical Importance.
XIIth National CME in Hematology, 2006, by Dr M B Agarwal.

7.

Reena Nair, Vikram GS. Mantle cell lymphoma : recent advances in the management. Hematology Update
– 2007. Practical Importance. XIIIth National CME in Hematology, 2007, by Dr M B Agarwal.

8.

Reena Nair, Vikram GS. Follicular lymphoma : Towards Cure. Hematology Update – 2008. Practical
Importance. XIVth National CME in Hematology, 2007, by Dr M B Agarwal.

11

9.

Reena Nair. Gastric MALT Lymphoma : Towards Cure. Hematology Update – 2009. Practical Importance.
XIVth National CME in Hematology, 2008, by Dr M B Agarwal.

10. Sriram Ravichandran, Reena Nair. An approach to a patient with Lymphadenopathy: Hematology Update –
2015. Practical Importance. XVth National CME in Hematology, 2015, by Dr M B Agarwal.
Publications- Conference Papers
1.

Myleodysplastic syndrome: a clinical and pathological analysis of 88 patients. XIV annual conference of
Bombay Haematology Group, February, 1990.

2.

Myelodysplastic syndrome. Annual conference of Association of physicians of India, January 1991.

3.

Modified MACOP-B chemotherapy for intermediate and high grade non-Hodgkin's lymphoma. VII Biennial
conference of Indian association of cancer chemotherapists, Ahmedabad, March 1993.

4.

Malignant germ cell tumours in childhood. VII Biennial conference of Indian association of cancer
chemotherapists, Ahmedabad, March 1993.

5.

MACOP-B vs MECOP-B in treatment of intermediate and high grade non Hodgkin's lymphoma. XVI
International Cancer Congress, New Delhi October 1994.

6.

(a) A prospective controlled study of the prevalence of Barrett's esophagusin cancer chemotherapy recipients,
pp XVI. International Cancer Congress, New Delhi, October 1994, pp 441.
(b) and at Indian Society of Gastroentrology 1995; Cuttack.

7.

Results of treatment with MACOP-B and Salvage therapy with MINE in Intermediate - and High- grade Non
Hodgkins Lymphoma. ISMPO 1995; Bangalore.

8.

All Trans Retinoic Acid and low dose Cytosine Arabinoside in patients with Myelodysplastic syndrome:
Results of a pilot study. ISMPO 1995; Bangalore.

9.

Non Hodgkins Lymphoma a randomised comparison of efficacy and toxicity of epirubicin versus doxorubicin.
12th Asia Pacific Cancer Conference 1995; Singapore.

10.

Retinoic acid syndrome in Acute Promyelocytic Leukemia. 37th Annual Connference, Indian Society of
Hematology and Blood Transfusion 1996; Chandigarh.

11.

Symposium on “Rationale of Dose Intensive Chemotherapy”. 37th Annual Conference, India Society of
Hematology and Blood Transfusion 1996; Chandigarh.

12.

Mantle Cell Lymphoma, a clinico-pathological study. 38th Annual Conference, Indian Society of Hematology
and Blood Transfusion 1997; Calcutta.

13.

Amifostine in Myelodysplastic Syndrome. Annual Conference, Bombay Hematology and Blood Trasnsfusion
February1998.

14.

BCL-2 translocation and expression in follicular and diffuse large B-cell lymphomas in India. IX Meeting
European Association for Haematopathology, April 1998, Leiden, The Netherland.

15.

Conducting Randomized Clinical Trials in the Developing Countries. Asian Clinical Trials Conference, Hong
Kong, October 1998.

16.

Pediatric Germ Cell Tumours. Pediatric Hematology Oncology Chapter IAP, Mumbai, December 1998.

17.

Chemotherapy Drugs at skill station. Pediatric Hematology Oncology Chapter IAP, Mumbai, December 1998.

18.

Conducting Randomized Clinical Trials in a Tertiary Cancer Hospital at ISMPO, Jodhpur, January 1999.

19.

Low Grade NHL - controversies in treatment. Symposium on Newer Developments in Hematology at 23rd
Annual Conference of BHG, Mumbai, February 1999.

20.

Acute Promyelocytic Leukemia : All Trans-Retinoic Acid along with Daunomycin followed by Arsenic
Trioxide as Sequential Therapy at 23rd Annual Conference of BHG, Mumbai, February 1999.

21.

Acute Promyelocytic Leukemia : All Trans Retinoic Acid along with Daunomycin Followed by Arsenic
Trioxide as Sequential Therapy. (Abs No. 87) ASCO 1999.

22.

Role of Amifostine in Patients with Aggressive Myelodysplastic Syndromes, (Leukemia Research. April
1999; Vol 23, Supp1 : Abs No. 206, Pg S78) at Vth Myelodysplastic Syndrome Conference, Prague, Czech
Republic, May 1999.

12

23.

Systemic Treatment of Breast Cancer. Workshop on Training of Trainers on Prevention, Early Detection and
Treatment of Breast Cancer. Organised by Dept. of Preventive Oncology, September 1999.

24.

Quality of Life in Cancer Patients. Symposium titled "Newer Horizons in Supportive Cancer Management" at
XXI National Conference, AROI, Calcutta, December 1999.

25.

Supportive Oncology Care. Symposium at Bharatpur Cancer Hospital - NEPAL, December 1999.

26.

Acute Promyelocytic Leukemia: All Trans Retinoic Acid along with Daunomycin followed by Arsenic
Trioxide as sequential therapy. XV Asia Pacific Cancer Conference, Chennai, December 1999.

27.

Clinical Survey: The impact of anemia and fatigue on Cancer patients. XV Asia Pacific Cancer Conference,
Chennai, December 1999.

28.

Role of Amifostine in patients with Aggressive Myelodysplastic Syndromes. XV Asia Pacific Cancer
Conference, Chennai, December 1999.

29.

Acute Promyelocytic Leukemia : All Trans Retinoic Acid along with Daunomycin followed by Arsenic
Trioxide as sequential therapy at 24th Annual Conference of Bombay Hematology Group, February 2000.

30.

Clinical Survey: The impact of anemia and fatigue on Cancer patients at 24th Annual Conference of Bombay
Hematology Group, February 2000.

31.

Role of Amifostine in patients with Aggressive Myelodysplastic Syndromes at 24th Annual Conference of
Bombay Hematology Group, February 2000.

32.

Acute Promyelocytic Leukemia: All trans retinoic acid along with daunomycin followed by Arsenic trioxide
as sequential therapy. 28th World Congress of the International Society of Hematology (ISH 2000), Toronto,
August 2000.

33.

Acute Promyelocytic Leukemia : All Trans Retinoic Acid along with Daunomycin followed by Arsenic
Trioxide as Sequential Therapy at Indian Society Medical & Pediatric Oncology, Hyderabad January 2001.

34.

Acute Promyelocytic Leukemia : All Trans Retinoic Acid along with Daunomycin followed by Arsenic
Trioxide as Sequential Therapy at 11th International Congress on Anti Cancer Treatment, Paris, January 2001.

35.

Acute Promyelocytic Leukemia : All Trans Retinoic Acid along with Daunomycin followed by Arsenic
Trioxide as Sequential Therapy at American Society Cancer , San Francisco Proc Am Soc Clin Oncol
2001; 20: abstr 1213.

36.

Alternating Triple Therapy (CHOP-MINE-ESHAP) in large cell B phenotype, non Hodgkin's Lymphoma at
American Society Cancer, San Francisco Proc Am Soc Clin Oncol 2001; 20: abstr 1160.

37.

Acute Promyelocytic Leukemia: All trans retinoic acid along with Daunomycin followed by Arsenic trioxide
as sequential therapy, at the Joint International Congress on APL and Differentiation Therapy at Rome,
Italy poster presentation, Oct 2001.

38.

Alternating Triple Therapy (CHOP-MINE-ESHAP) in large cell B phenotype, non Hodgkin's Lymphoma
published in the proceedings of Lymphoma Conference at Lugano 2002.

41

Adjuvant Breast Cancer Trial (ABC) and the lessons learnt in conducting an Adjuvant Trial presented at the
close out meet NCRI Adjuvant Breast Cancer International Participants Meeting, London 2004.

42. Randomized phase II trial of three gemcitabine (GEM) – taxane combinations in
Metastatic breast cancer (MBC)(B9E-MC-S197). ASCO abstract 2004.
43. Ovarian ablation (OA) in permenopausal women with early breast cancer prescribed 5 years tamoxifen (T) or T
plus chemotherapy (CT) – Results from the UK NCRI Adjuvant Breast Cancer (ABC) International trial of
2144 patients. Poster at ASCO 2004
44. Polychemotherapy (CT) in pre and post-menopausal women with early breast cancer prescribed 5 years of
tamoxifen (T) - Results from the UK NCRI Adjuvant Breast Cancer (ABC) International trial of 1991 patients.
Poster at ASCO 2004
45. Thromboembolic events (TEC) in Adjuvant Breast Cancer (ABC) International trial –Retrospective and
Prospective audit. Poster at ASCO 2004.
46. Clonal IgVh dominance of B-CLL cells in response to chemokine SDF1. Poster presented at IACR (Ind J Med
Res 2005).

13

47. Selective migration of IgVH3+ B –cell CLL clones in response to chemokine SDF1. Poster at BSH 2006
48. To assess the effect of chemotherapy on reactivation of tuberculosis. Poster at ESMO, Istanbul 2006
49. Primary thyroid lymphomas. Single center experience. Poster at ESMO, Istanbul 2006.
50. Phase III study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally
advanced or metastatic breast cancer. Poster at the 29th, Annual San Antonio Breast Cancer Symposium,
2006 (one of the investigators).
51. Prospective study of pattern of IFI and role of latex agglutination in GM and CM antigen detection in patient
presenting with HR Neutropenic fever. JCO 26 : Abstract No – 20534 ; 20 May 2008
52. Risk factors for poor performance status in cancer patients : A multivariate analysis in 3585 patients. Proc
ASCO 2008; (20: abstr 9628).
53. Dr J G Parekh Oration at the 33rd, Annual conference of the Mumbai Hematology Group: Acute Promyelocytic
Leukemia – A journey from Curse to Cure 2010.
54. ISHTM HAEMATOCON Conference Kolkatta, Adolescent and Young Adult (AYA) Lymphomas 2010.
55. Phase II feasibility study of combination chemotherapy with fractionated endoxan, vinblastine, oral
etoposide and prednisolone in patients with Acquired immunodeficiency syndrome (AIDS) related
aggressive lymphomas. ICML, Lugano (abstract: 488) Ann of Oncol 2011; 22 (4): iv 236.
56. Comparison of toxicity and outcomes of BCNU-containing conditioning regimens versus LACE in
lymphoma transplants: A retrospective multicenter analysis. Indian Oncology Study Group (IOSG). Poster in
ASH 2011
57. Cytogenetic analysis helps identification of prognostic groups in Multiple Myeloma: the experience from Ind
J Mol Diag 2012; 14 (Abs# 459) pp 667.
58. Retrospective single center analysis of safety, efficacy and toxicity of Rituximab (original) and its biosimilar
in diffuse large B cell lymphoma patients treated with chemoimmunotherapy. ESMO Congress, Vienna
2012 (Abstract No 1074P)
59. Predicting response rates of High grade non Hodgkin’s lymphomas: a comparative study of International
Prognostic Index (IPI) with Subjective Global Assessment. ESMO Congress, Vienna2012 (Abstr No106242P)
60. Comparison of efficacy and safety of Rituximab (Mabthera and its biosimilar Reditux), in diffuse large B
cell lymphoma patients treated with chemoimmunotherapy: a retrospective analysis. ISHTM 2012, Puri.
61. Sequential Arsenic trioxide and all trans retinoic acid with daunomycin yield early cytogenetic and
molecular response in newly diagnosed acute promyelocytic leukemia- Data from a tertiary cancer center.
Poster in ASH 2012
62. Lateef Zameer, Divya Midha, Manjusha Biswas, Reena Nair. Leukemic infiltration of gall bladder,
masquerading as symptomatic cholelithiasis, unusual presentation in a known case of Chronic Lymphocytic
Leukemia. Poster presented at the RGCON 2014
63. Anupam Chakrapani, Bhave Sourav, Mayur Parihar, Neeraj Arora, Sanjay Bhattacharya, Deepak Mishra ,
Reena Nair, Mammen Chandy. Decitabine as bridge to definitive therapy for Acute Myeloid Leukemia and
Myelodysplastic Syndrome: Experience of a tertiary cancer center from India. Oral Presentation at the ACE
Meeting Aug 2014, Mumbai
64. Myeloablative Haploidentical Stem Cell Transplantation (PTCy) in Relapse /Refractory Acute Myeloid
leukemia: A single center experience. Oral Paper Hematocon 2014, Mumbai 6th to 9th November.
65. Champa Ghosh, Chandrayee Sarker, Pulak Paik, Sriram Ravichandran, Saurabh Bhave, Anupam
Chakrapani, Neeraj Arora, Rimpa Basu, Mammen Chandy, Reena Nair. Demography and early treatment
outcomes of lymphomas: Prospective EMR data. ISMPO 2015, Mumbai 6 th to 9th Novemeber,
66. Sriram Ravichandran, Neeraj Arora, Indu Arun, Bhave Saurabh Jayant, Anupam Chakrapani, Mammen
Chandy, Reena Nair. NK/T-cell lymphoma: A reason to SMILE. ISMPO 2015, Mumbai 6th to 9th
Novmeber.
67. Rohith.G.Chitrapur, Sriram Ravichandran,Saurabh Bhave Jayant, Anupam Chakrapani, Reena Nair,
Mammen Chandy. R-DA-EPOCH in high grade lymphoma- Single center experience. Hematocon 2015,
Bangalore 2015 7th to 9th November.
68. Chandrayee Sarker, Champa Ghosh, Pulak Paik, Neeraj Arora, Sourabh Bhave, Anupam Chakrapani, Rimpa
Basu Achari, Mammen Chandy, Reena Nair. We too see elderly patients with Lymphoma in our clinics.
ISMPO 2015, Mumbai 6th to 9th November.
69. Patel U, Arun SR, Yadav A, Gore A, Mishra DK, Arora N, Bhattacharya A, Krishnan S, Saha V, Bhave S,
Chakrapani A, Nair R, Chandy M, Parihar M. Cytogenetic And Molecular Profile Of Acute Myeloid

14

Leukemia (AML) From A Tertiary Care centre In Eastern India. Hematocon 2015, Bangalore 2015 7 th to 9th
November.
Awards – during my college days
1.
Laxmibai Korane prize for standing first in Goa Medical college, Ist MB,BS.
2.

Goa Medical College First Prize in Human Anatomy, for proficiency at MB,BS, university examinations

Orations
S.No Year
1.
2010

Topic and meeting
Acute Promyelocytic Leukemia – A journey form Curse to Cure. Dr JG Parekh Oration at the
33rd, Annual Conference of the Mumbai Hematology Group.

2.

2011

Clinical Trials- Facts and Myths. Advances in Science, Engineering and Technology (ASET)
colloquia, Tata Institute of Fundamental Research, Mumbai.

Awards – during my tenure as convener Hematolo-Lymphoid (Adult) DMG, TMH, Mumbai 2009- 2012
S.No Year
Topic and meeting
1.
2010
2nd, Prize for Oral Presentation-Adolescent and Young Adult (AYA), lymphomas. (Reena
Nair) ISHTM HAEMATOCON Conference, Kolkatta
2.

2011

3.

2012

1st, Prize for Oral Presentation- Long Term Outcomes of Bone Marrow Transplantation in
Multiple Myeloma. (Bhausaheb Bagal) Mumbai Hematology Group 35th Annual Meet.
1st, Prize for Oral Presentation - A phase II feasibility study of combination therapy with
fractionated cyclophosphamide, vinblastine, oral etoposide and prednisolone in patients with
Acquired Immunodeficiency Syndrome (AIDS) related aggressive lymphomas. (Manju
Sengar). Lymphoma and Leukemia 2012 (ESO), Mumbai.

4.

2012

3rd, Prize for Oral Presentation – SMILE for peripheral T cell lymphoma- an effective and safe
regimen. (Seema Gulia). Lymphoma and Leukemia 2012 (ESO).

5.

2012

1st, Prize for Poster Presentation- CD 200 expression in lymphoid cells of non Hodgkin’s
lymphomas involving the bone marrow and peripheral blood.(Neha Mittal). Lymphoma and
Leukemia 2012 (ESO).

6.

2012

3rd, Prize for Poster Presentation – Dasatinib in second line treatment for Chronic Myeloid
leukemia- a single centre experience. (Shilpa Gupta). Lymphoma and Leukemia 2012

7.

2012

1st Prize for Poster Presentation - Predicting early outcomes of non Hodgkin’s lymphoma: A
comparative study of International Prognostic Index (IPI) with Subjective Global Assessment
(SGA). (Vikas Ostwal) Mumbai Hematology Group 36th Annual Meet.

8.

2012

2nd, Prize for Oral Presentation – Phase II feasibility study of Oral Metronomic
chemotherapy-ME2C in adult patients with relapsed/refractory High grade B cell NonHodgkin’s lymphoma not eligible for stem cell transplantation. (Ravi Thippeswamy)
Mumbai Hematology Group 36th Annual Meet.

15


Related documents


2016010408 10 48reena nair cv 2016
dr griesinger veroeffentlichungen
riches cv march 2016
55 4
cv federico massimo
jdit 2016 0712 022

Link to this page


Permanent link

Use the permanent link to the download page to share your document on Facebook, Twitter, LinkedIn, or directly with a contact by e-Mail, Messenger, Whatsapp, Line..

Short link

Use the short link to share your document on Twitter or by text message (SMS)

HTML Code

Copy the following HTML code to share your document on a Website or Blog

QR Code

QR Code link to PDF file 2016.01.04_08-10-48Reena Nair cv 2016.pdf